<DOC>
	<DOCNO>NCT01933932</DOCNO>
	<brief_summary>The purpose study assess efficacy selumetinib combination docetaxel ( 75mg/m2 ) v placebo combination docetaxel ( 75mg/m2 ) patient locally advance metastatic NSCLCs harbor mutation KRAS . This study also assess PK , safety , patient report outcome ( PRO ) tolerability profile selumetinib/docetaxel combination , compare placebo combination docetaxel</brief_summary>
	<brief_title>Assess Efficacy &amp; Safety Selumetinib Combination With Docetaxel Patients Receiving 2nd Line Treatment v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog ( KRAS ) Positive NSCLC</brief_title>
	<detailed_description>A Phase III , Double-Blind , Randomised , Placebo-Controlled Study Assess Efficacy Safety Selumetinib ( AZD6244 ; ARRY-142886 ) ( Hyd-Sulfate ) Combination Docetaxel , Patients receive second line treatment KRAS Mutation-Positive Locally Advanced Metastatic Non Small Cell Lung Cancer ( Stage IIIB - IV ) ( SELECT-1 )</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Provision sign , write date informed consent prior study specific procedure Male female , age 18 year old Histological cytological confirmation locally advance metastatic NSCLC ( IIIBIV ) KRAS mutation positive tumour sample determine designated test laboratory Failure 1st line anticancer therapy due radiological documentation disease progression advance disease subsequent relapse disease follow 1st line therapy Mixed small cell nonsmall cell lung cancer histology . Received &gt; 1 prior anticancer drug regimen advance metastatic NSCLC . Patients develop disease progression switch maintenance therapy ( maintenance use agent firstline regimen ) eligible . Receiving received systemic anticancer therapy within 30 day prior start study treatment Other concomitant anticancer therapy agent except steroid Prior treatment MitogenActivated protein Kinase ( MEK ) inhibitor docetaxelcontaining regimen ( prior treatment paclitaxel acceptable ) . Last radiation therapy within 4 week prior start study treatment , limited field radiation palliation within 7 day first dose study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Mitogen-Activated Protein Kinase Kinase inhibitor ; Non Small Cell Lung Cancer ; metastatic ; second line treatment Non Small Cell Lung Cancer ; KRAS mutation</keyword>
</DOC>